WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005

Jan Willem van der Laan, Philip Minor, Richard Mahoney, Charles Arntzen, Jinho Shin, David Wood

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In January 2005, WHO convened a meeting of leading experts in plant-derived vaccines and experts from regulatory authorities for an informal discussion on the state-of-the-art and to analyse whether specific guidance might be needed for plant-derived vaccines that is not yet provided by regulatory authorities. After a series of individual presentations, a general discussion was held to obtain a consensus on the need for further guidance. Both the presentations and the conclusions are presented. The meeting concluded that existing guidelines for the development, evaluation, and use of vaccines made by traditional methods can be applied to plant-derived vaccines. For plant-derived vaccines some specific issues will have to be addressed. These include, but are not restricted to, containment of the plants including disposal of waste materials. It was noted that plant-derived vaccines have been produced and clinically tested under US investigational new drug application, and all applicable regulatory and good manufacturing practice requirements are in place for this type of product. An innovator wishing to bring a plant-derived vaccine to market should consult closely with regulatory authorities to ensure that all appropriate studies are undertaken.

Original languageEnglish (US)
Pages (from-to)4271-4278
Number of pages8
JournalVaccine
Volume24
Issue number20
DOIs
StatePublished - May 15 2006

Fingerprint

Switzerland
Referral and Consultation
Vaccines
vaccines
Investigational New Drug Application
good manufacturing practices
waste disposal
new drugs
Guidelines
markets

Keywords

  • Plants
  • Vaccines
  • World Health Organization

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005. / van der Laan, Jan Willem; Minor, Philip; Mahoney, Richard; Arntzen, Charles; Shin, Jinho; Wood, David.

In: Vaccine, Vol. 24, No. 20, 15.05.2006, p. 4271-4278.

Research output: Contribution to journalArticle

van der Laan, Jan Willem ; Minor, Philip ; Mahoney, Richard ; Arntzen, Charles ; Shin, Jinho ; Wood, David. / WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005. In: Vaccine. 2006 ; Vol. 24, No. 20. pp. 4271-4278.
@article{f48cb0af0a3c45b9b239934f383ab492,
title = "WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005",
abstract = "In January 2005, WHO convened a meeting of leading experts in plant-derived vaccines and experts from regulatory authorities for an informal discussion on the state-of-the-art and to analyse whether specific guidance might be needed for plant-derived vaccines that is not yet provided by regulatory authorities. After a series of individual presentations, a general discussion was held to obtain a consensus on the need for further guidance. Both the presentations and the conclusions are presented. The meeting concluded that existing guidelines for the development, evaluation, and use of vaccines made by traditional methods can be applied to plant-derived vaccines. For plant-derived vaccines some specific issues will have to be addressed. These include, but are not restricted to, containment of the plants including disposal of waste materials. It was noted that plant-derived vaccines have been produced and clinically tested under US investigational new drug application, and all applicable regulatory and good manufacturing practice requirements are in place for this type of product. An innovator wishing to bring a plant-derived vaccine to market should consult closely with regulatory authorities to ensure that all appropriate studies are undertaken.",
keywords = "Plants, Vaccines, World Health Organization",
author = "{van der Laan}, {Jan Willem} and Philip Minor and Richard Mahoney and Charles Arntzen and Jinho Shin and David Wood",
year = "2006",
month = "5",
day = "15",
doi = "10.1016/j.vaccine.2005.12.063",
language = "English (US)",
volume = "24",
pages = "4271--4278",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "20",

}

TY - JOUR

T1 - WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005

AU - van der Laan, Jan Willem

AU - Minor, Philip

AU - Mahoney, Richard

AU - Arntzen, Charles

AU - Shin, Jinho

AU - Wood, David

PY - 2006/5/15

Y1 - 2006/5/15

N2 - In January 2005, WHO convened a meeting of leading experts in plant-derived vaccines and experts from regulatory authorities for an informal discussion on the state-of-the-art and to analyse whether specific guidance might be needed for plant-derived vaccines that is not yet provided by regulatory authorities. After a series of individual presentations, a general discussion was held to obtain a consensus on the need for further guidance. Both the presentations and the conclusions are presented. The meeting concluded that existing guidelines for the development, evaluation, and use of vaccines made by traditional methods can be applied to plant-derived vaccines. For plant-derived vaccines some specific issues will have to be addressed. These include, but are not restricted to, containment of the plants including disposal of waste materials. It was noted that plant-derived vaccines have been produced and clinically tested under US investigational new drug application, and all applicable regulatory and good manufacturing practice requirements are in place for this type of product. An innovator wishing to bring a plant-derived vaccine to market should consult closely with regulatory authorities to ensure that all appropriate studies are undertaken.

AB - In January 2005, WHO convened a meeting of leading experts in plant-derived vaccines and experts from regulatory authorities for an informal discussion on the state-of-the-art and to analyse whether specific guidance might be needed for plant-derived vaccines that is not yet provided by regulatory authorities. After a series of individual presentations, a general discussion was held to obtain a consensus on the need for further guidance. Both the presentations and the conclusions are presented. The meeting concluded that existing guidelines for the development, evaluation, and use of vaccines made by traditional methods can be applied to plant-derived vaccines. For plant-derived vaccines some specific issues will have to be addressed. These include, but are not restricted to, containment of the plants including disposal of waste materials. It was noted that plant-derived vaccines have been produced and clinically tested under US investigational new drug application, and all applicable regulatory and good manufacturing practice requirements are in place for this type of product. An innovator wishing to bring a plant-derived vaccine to market should consult closely with regulatory authorities to ensure that all appropriate studies are undertaken.

KW - Plants

KW - Vaccines

KW - World Health Organization

UR - http://www.scopus.com/inward/record.url?scp=33646127991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646127991&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.12.063

DO - 10.1016/j.vaccine.2005.12.063

M3 - Article

C2 - 16767805

AN - SCOPUS:33646127991

VL - 24

SP - 4271

EP - 4278

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 20

ER -